Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Armodafinil as a Potential Pharmacological Treatment for Attention Deficit Hyperactivity Disorder in Adults: A Review

Author(s): Reyna Lamas-Aguilar, Araceli Diaz-Ruiz, Luz Navarro, Raúl Miranda-Ojeda, María de los Ángeles Martínez-Cárdenas, Alfonso Mata-Bermudez* and Camilo Rios*

Volume 22, Issue 11, 2024

Published on: 14 March, 2024

Page: [1899 - 1908] Pages: 10

DOI: 10.2174/1570159X22666240131121642

Price: $65

Abstract

Introduction: Armodafinil is a psychostimulant that promotes alertness, and it has been shown to improve attention, memory, and fatigue in healthy adults and adults with neurodevelopmental conditions that share symptoms with Attention Deficit Hyperactivity Disorder (ADHD). It is generally well tolerated and safe, and most of the adverse events reported are considered not serious. However, the available evidence on the efficacy of armodafinil for the treatment of ADHD in adults is scarce.

Objective: The present review aims to perform a systematized search of the available evidence on the possible therapeutic benefit of armodafinil treatment in adult patients with ADHD.

Methods: A literature review using PubMed was conducted to compile and summarize the available clinical and scientific evidence on the possible use of armodafinil as a pharmacological treatment in adult patients with ADHD.

Results: From the 86 articles reviewed, the available evidence showed that both acute and chronic treatment with armodafinil can improve wakefulness, memory, impulse control, and executive functions in adults with sleep disorders and other conditions. In addition, evidence of improvement in cognitive functions and mood alterations in other neuropsychiatric conditions was shown.

Conclusion: Armodafinil could be useful for the treatment of ADHD in adults, according to the review of the literature from both pre-clinical and clinical studies.

« Previous Next »
Graphical Abstract

[1]
Salvi, V.; Migliarese, G.; Venturi, V.; Rossi, F.; Torriero, S.; Viganò, V.; Cerveri, G.; Mencacci, C. ADHD in adults: Clinical subtypes and associated characteristics. Riv. Psichiatr., 2019, 54(2), 84-89.
[http://dx.doi.org/10.1708/3142.31249] [PMID: 30985833]
[2]
Memarmoghaddam, M.; Torbati, H.T.; Sohrabi, M.; Mashhadi, A.; Kashi, A. Effects of a selected exercise programon executive function of children with attention deficit hyperactivity disorder. J. Med. Life, 2016, 9(4), 373-379.
[http://dx.doi.org/10.22336/jml.2016.0410] [PMID: 27928441]
[3]
Spera, V.; Maiello, M.; Pallucchini, A.; Novi, M.; Elefante, C.; De Dominicis, F.; Palagini, L.; Biederman, J.; Perugi, G. Adult attention-deficit hyperactivity disorder and clinical correlates of delayed sleep phase disorder. Psychiatry Res., 2020, 291, 113162.
[http://dx.doi.org/10.1016/j.psychres.2020.113162] [PMID: 32554185]
[4]
Wolraich, M.L.; Hagan, J.F., Jr; Allan, C.; Chan, E.; Davison, D.; Earls, M.; Evans, S.W.; Flinn, S.K.; Froehlich, T.; Frost, J.; Holbrook, J.R.; Lehmann, C.U.; Lessin, H.R.; Okechukwu, K.; Pierce, K.L.; Winner, J.D.; Zurhellen, W. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/] hyperactivity disorder in children and adolescents. Pediatrics, 2019, 144(4), e20192528.
[http://dx.doi.org/10.1542/peds.2019-2528] [PMID: 31570648]
[5]
Kazda, L.; McGeechan, K.; Bell, K.; Thomas, R.; Barratt, A. Association of attention-deficit/hyperactivity disorder diagnosis with adolescent quality of life. JAMA Netw. Open, 2022, 5(10), e2236364.
[http://dx.doi.org/10.1001/jamanetworkopen.2022.36364] [PMID: 36227598]
[6]
Katzman, M.A.; Bilkey, T.S.; Chokka, P.R.; Fallu, A.; Klassen, L.J. Adult ADHD and comorbid disorders: Clinical implications of a dimensional approach. BMC Psychiatry, 2017, 17(1), 302.
[http://dx.doi.org/10.1186/s12888-017-1463-3] [PMID: 28830387]
[7]
Gift, T.E.; Reimherr, F.W.; Marchant, B.K.; Steans, T.A.; Wender, P.H. Personality disorder in adult attention-deficit/hyperactivity disorder. J. Nerv. Ment. Dis., 2016, 204(5), 355-363.
[http://dx.doi.org/10.1097/NMD.0000000000000470] [PMID: 27082828]
[8]
Salvi, V.; Ribuoli, E.; Servasi, M.; Orsolini, L.; Volpe, U. ADHD and bipolar disorder in adulthood: Clinical and treatment implications. Medicina, 2021, 57(5), 466.
[http://dx.doi.org/10.3390/medicina57050466] [PMID: 34068605]
[9]
Ginsberg, Y.; Quintero, J.; Anand, E.; Casillas, M.; Upadhyaya, H.P. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: A review of the literature. Prim. Care Comp. CNS Disord., 2014, 16(3), PCC.13r01600.
[http://dx.doi.org/10.4088/PCC.13r01600] [PMID: 25317367]
[10]
Coelho, R.M.; Drummond, C.; Mota, N.B.; Erthal, P.; Bernardes, G.; Lima, G.; Molina, R.; Sudo, F.K.; Tannock, R.; Mattos, P. Network analysis of narrative discourse and attention-deficit hyperactivity symptoms in adults. PLoS One, 2021, 16(4), e0245113.
[http://dx.doi.org/10.1371/journal.pone.0245113] [PMID: 33826632]
[11]
Nelson, J.M.; Liebel, S.W. Anxiety and depression among college students with attention-deficit/hyperactivity disorder (ADHD): Cross-informant, sex, and subtype differences. J. Am. Coll. Health, 2018, 66(2), 123-132.
[http://dx.doi.org/10.1080/07448481.2017.1382499] [PMID: 28937938]
[12]
Posner, J.; Polanczyk, G.V.; Sonuga-Barke, E. Attention-deficit hyperactivity disorder. Lancet, 2020, 395(10222), 450-462.
[http://dx.doi.org/10.1016/S0140-6736(19)33004-1] [PMID: 31982036]
[13]
Young, J.L.; Goodman, D.W. Adult attention-deficit/hyperactivity disorder diagnosis, management, and treatment in the DSM-5 era. Prim. Care Companion CNS Disord., 2016, 18(6), 10.4088/PCC.16r02000.
[http://dx.doi.org/10.4088/PCC.16r02000] [PMID: 27907271]
[14]
Turner, D.C.; Clark, L.; Dowson, J.; Robbins, T.W.; Sahakian, B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry, 2004, 55(10), 1031-1040.
[http://dx.doi.org/10.1016/j.biopsych.2004.02.008] [PMID: 15121488]
[15]
Loland, C.J.; Mereu, M.; Okunola, O.M.; Cao, J.; Prisinzano, T.E.; Mazier, S.; Kopajtic, T.; Shi, L.; Katz, J.L.; Tanda, G.; Newman, A.H. R-modafinil (armodafinil): A unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol. Psychiatry, 2012, 72(5), 405-413.
[http://dx.doi.org/10.1016/j.biopsych.2012.03.022] [PMID: 22537794]
[16]
Boellner, S.W.; Earl, C.Q.; Arora, S. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: A preliminary 8-week, open-label study. Curr. Med. Res. Opin., 2006, 22(12), 2457-2465.
[http://dx.doi.org/10.1185/030079906X148300] [PMID: 17257460]
[17]
Swanson, J.M.; Greenhill, L.L.; Lopez, F.A.; Sedillo, A.; Earl, C.Q.; Jiang, J.G.; Biederman, J. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: Results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J. Clin. Psychiatry, 2006, 67(1), 137-147.
[http://dx.doi.org/10.4088/JCP.v67n0120] [PMID: 16426100]
[18]
Gao, W-J.; Urban, K.R. Psychostimulants as cognitive enhancers in adolescents: More risk than reward? Front. Public Health, 2017, 5, 260.
[http://dx.doi.org/10.3389/fpubh.2017.00260] [PMID: 29034227]
[19]
Minzenberg, M.J.; Carter, C.S. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 2008, 33(7), 1477-1502.
[http://dx.doi.org/10.1038/sj.npp.1301534] [PMID: 17712350]
[20]
Del-Ponte, B.; Anselmi, L.; Assunção, M.C.F.; Tovo-Rodrigues, L.; Munhoz, T.N.; Matijasevich, A.; Rohde, L.A.; Santos, I.S. Sugar consumption and attention-deficit/hyperactivity disorder (ADHD): A birth cohort study. J. Affect. Disord., 2019, 243, 290-296.
[http://dx.doi.org/10.1016/j.jad.2018.09.051] [PMID: 30257225]
[21]
Kerekes, N.; Sanchéz-Pérez, A.M.; Landry, M. Neuroinflammation as a possible link between attention-deficit/hyperactivity disorder (ADHD) and pain. Med. Hypotheses, 2021, 157, 110717.
[http://dx.doi.org/10.1016/j.mehy.2021.110717] [PMID: 34717072]
[22]
Sharma, A.; Couture, J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann. Pharmacother., 2014, 48(2), 209-225.
[http://dx.doi.org/10.1177/1060028013510699] [PMID: 24259638]
[23]
Adler, L.A.; Faraone, S.V.; Spencer, T.J.; Berglund, P.; Alperin, S.; Kessler, R.C. The structure of adult ADHD. Int. J. Methods Psychiatr. Res., 2017, 26(1), e1555.
[http://dx.doi.org/10.1002/mpr.1555] [PMID: 28211596]
[24]
Das, D.; Cherbuin, N.; Butterworth, P.; Anstey, K.J.; Easteal, S. A population-based study of attention deficit/hyperactivity disorder symptoms and associated impairment in middle-aged adults. PLoS One, 2012, 7(2), e31500.
[http://dx.doi.org/10.1371/journal.pone.0031500] [PMID: 22347487]
[25]
Biederman, J.; Faraone, S.V.; Spencer, T.J.; Mick, E.; Monuteaux, M.C.; Aleardi, M. Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community. J. Clin. Psychiatry, 2006, 67(4), 524-540.
[http://dx.doi.org/10.4088/JCP.v67n0403] [PMID: 16669717]
[26]
Fayyad, J.; De Graaf, R.; Kessler, R.; Alonso, J.; Angermeyer, M.; Demyttenaere, K.; De Girolamo, G.; Haro, J.M.; Karam, E.G.; Lara, C.; Lépine, J.P.; Ormel, J.; Posada-Villa, J.; Zaslavsky, A.M.; Jin, R. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br. J. Psychiatry, 2007, 190(5), 402-409.
[http://dx.doi.org/10.1192/bjp.bp.106.034389] [PMID: 17470954]
[27]
Crunelle, C.L.; van den Brink, W.; Moggi, F.; Konstenius, M.; Franck, J.; Levin, F.R.; van de Glind, G.; Demetrovics, Z.; Coetzee, C.; Luderer, M.; Schellekens, A.; Matthys, F. International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder. Eur. Addict. Res., 2018, 24(1), 43-51.
[http://dx.doi.org/10.1159/000487767] [PMID: 29510390]
[28]
Castells, X.; Blanco-Silvente, L.; Cunill, R. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Libr., 2018, 2018(8), CD007813.
[http://dx.doi.org/10.1002/14651858.CD007813.pub3] [PMID: 30091808]
[29]
Johnson, J.; Morris, S.; George, S. Attention deficit hyperactivity disorder in adults: What the non-specialist needs to know. Br. J. Hosp. Med., 2020, 81(3), 1-11.
[http://dx.doi.org/10.12968/hmed.2019.0188] [PMID: 32240011]
[30]
Jaeschke, R.R.; Sujkowska, E.; Sowa-Kućma, M. Methylphenidate for attention-deficit/hyperactivity disorder in adults: A narrative review. Psychopharmacology, 2021, 238(10), 2667-2691.
[http://dx.doi.org/10.1007/s00213-021-05946-0] [PMID: 34436651]
[31]
Cortese, S.; Adamo, N.; Del Giovane, C.; Mohr-Jensen, C.; Hayes, A.J.; Carucci, S.; Atkinson, L.Z.; Tessari, L.; Banaschewski, T.; Coghill, D.; Hollis, C.; Simonoff, E.; Zuddas, A.; Barbui, C.; Purgato, M.; Steinhausen, H.C.; Shokraneh, F.; Xia, J.; Cipriani, A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 2018, 5(9), 727-738.
[http://dx.doi.org/10.1016/S2215-0366(18)30269-4] [PMID: 30097390]
[32]
Greenhill, L.L.; Pliszka, S.; Dulcan, M.K.; Bernet, W.; Arnold, V.; Beitchman, J.; Benson, R.S.; Bukstein, O.; Kinlan, J.; McClellan, J.; Rue, D.; Shaw, J.A.; Stock, S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J. Am. Acad. Child Adolesc. Psychiatry, 2002, 41(2), 26S-49S.
[http://dx.doi.org/10.1097/00004583-200202001-00003] [PMID: 11833633]
[33]
Pozzi, M.; Bertella, S.; Gatti, E.; Peeters, G.G.A.M.; Carnovale, C.; Zambrano, S.; Nobile, M. Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD). Expert Opin. Emerg. Drugs, 2020, 25(4), 395-407.
[http://dx.doi.org/10.1080/14728214.2020.1820481] [PMID: 32938246]
[34]
Rugino, T. A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents. Neuropsychiatr. Dis. Treat., 2007, 3(3), 293-301.
[PMID: 19300563]
[35]
Biederman, J.; Faraone, S.V. Attention-deficit hyperactivity disorder. Lancet, 2005, 366(9481), 237-248.
[http://dx.doi.org/10.1016/S0140-6736(05)66915-2] [PMID: 16023516]
[36]
Adler, L.A.; Liebowitz, M.; Kronenberger, W.; Qiao, M.; Rubin, R.; Hollandbeck, M.; Deldar, A.; Schuh, K.; Durell, T. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress. Anxiety, 2009, 26(3), 212-221.
[http://dx.doi.org/10.1002/da.20549] [PMID: 19194995]
[37]
Walters, A.S.; Silvestri, R.; Zucconi, M.; Chandrashekariah, R.; Konofal, E. Review of the possible relationship and hypothetical links between attention deficit hyperactivity disorder (ADHD) and the simple sleep related movement disorders, parasomnias, hypersomnias, and circadian rhythm disorders. J. Clin. Sleep Med., 2008, 4(6), 591-600.
[http://dx.doi.org/10.5664/jcsm.27356] [PMID: 19110891]
[38]
van Andel, E.; Bijlenga, D.; Vogel, S.W.N.; Beekman, A.T.F.; Kooij, J.J.S. Attention-deficit/hyperactivity disorder and delayed sleep phase syndrome in adults: A randomized clinical trial on the effects of chronotherapy on sleep. J. Biol. Rhythms, 2022, 37(6), 673-689.
[http://dx.doi.org/10.1177/07487304221124659] [PMID: 36181304]
[39]
Gamble, K.L.; May, R.S.; Besing, R.C.; Tankersly, A.P.; Fargason, R.E. Delayed sleep timing and symptoms in adults with attention-deficit/hyperactivity disorder: A controlled actigraphy study. Chronobiol. Int., 2013, 30(4), 598-606.
[http://dx.doi.org/10.3109/07420528.2012.754454] [PMID: 23445512]
[40]
Gau, S.S.F.; Kessler, R.C.; Tseng, W.L.; Wu, Y.Y.; Chiu, Y.N.; Yeh, C.B.; Hwu, H.G. Association between sleep problems and symptoms of attention-deficit/hyperactivity disorder in young adults. Sleep, 2007, 30(2), 195-201.
[http://dx.doi.org/10.1093/sleep/30.2.195] [PMID: 17326545]
[41]
Mahajan, N.; Hong, N.; Wigal, T.L.; Gehricke, J.G. Hyperactive-impulsive symptoms associated with self-reported sleep quality in nonmedicated adults with ADHD. J. Atten. Disord., 2010, 14(2), 132-137.
[http://dx.doi.org/10.1177/1087054709347170] [PMID: 19767595]
[42]
Kooij, J.J.S.; Bijlenga, D. The circadian rhythm in adult attention-deficit/hyperactivity disorder: current state of affairs. Expert Rev. Neurother., 2013, 13(10), 1107-1116.
[http://dx.doi.org/10.1586/14737175.2013.836301] [PMID: 24117273]
[43]
Zisapel, N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br. J. Pharmacol., 2018, 175(16), 3190-3199.
[http://dx.doi.org/10.1111/bph.14116] [PMID: 29318587]
[44]
Baird, A.L.; Coogan, A.N.; Siddiqui, A.; Donev, R.M.; Thome, J. Adult attention-deficit hyperactivity disorder is associated with alterations in circadian rhythms at the behavioural, endocrine and molecular levels. Mol. Psychiatry, 2012, 17, 988-995.
[http://dx.doi.org/10.1038/mp.2011.149]
[45]
Coogan, A.N.; Baird, A.L.; Popa-Wagner, A.; Thome, J. Circadian rhythms and attention deficit hyperactivity disorder: The what, the when and the why. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 67, 74-81.
[http://dx.doi.org/10.1016/j.pnpbp.2016.01.006] [PMID: 26776072]
[46]
Parekh, P.K.; Ozburn, A.R.; McClung, C.A. Circadian clock genes: Effects on dopamine, reward and addiction. Alcohol, 2015, 49(4), 341-349.
[http://dx.doi.org/10.1016/j.alcohol.2014.09.034] [PMID: 25641765]
[47]
Hirshkowitz, M.; Black, J.E.; Wesnes, K.; Niebler, G.; Arora, S.; Roth, T. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Respir. Med., 2007, 101(3), 616-627.
[http://dx.doi.org/10.1016/j.rmed.2006.06.007] [PMID: 16908126]
[48]
Sousa, A.; Dinis-Oliveira, R.J. Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects. Subst. Abus., 2020, 41(2), 155-173.
[http://dx.doi.org/10.1080/08897077.2019.1700584] [PMID: 31951804]
[49]
Schwartz, J.; Roth, T.; Drake, C. Armodafinil in the treatment of sleep/wake disorders. Neuropsychiatr. Dis. Treat., 2010, 6, 417-427.
[http://dx.doi.org/10.2147/NDT.S3004] [PMID: 20856606]
[50]
Wang, S.M.; Han, C.; Lee, S.J.; Jun, T.Y.; Patkar, A.A.; Masand, P.S.; Pae, C.U. Modafinil for the treatment of attention-deficit/hyperactivity disorder: A meta-analysis. J. Psychiatr. Res., 2017, 84, 292-300.
[http://dx.doi.org/10.1016/j.jpsychires.2016.09.034] [PMID: 27810669]
[51]
Turner, D.C.; Robbins, T.W.; Clark, L.; Aron, A.R.; Dowson, J.; Sahakian, B.J. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology, 2003, 165(3), 260-269.
[http://dx.doi.org/10.1007/s00213-002-1250-8] [PMID: 12417966]
[52]
Taylor, F.B.; Russo, J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J. Child Adolesc. Psychopharmacol., 2000, 10(4), 311-320.
[http://dx.doi.org/10.1089/cap.2000.10.311] [PMID: 11191692]
[53]
Amiri, S.; Mohammadi, M.R.; Mohammadi, M.; Nouroozinejad, G.H.; Kahbazi, M.; Akhondzadeh, S. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(1), 145-149.
[http://dx.doi.org/10.1016/j.pnpbp.2007.07.025] [PMID: 17765380]
[54]
Rugino, T.A.; Copley, T.C. Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J. Am. Acad. Child Adolesc. Psychiatry, 2001, 40(2), 230-235.
[http://dx.doi.org/10.1097/00004583-200102000-00018] [PMID: 11211372]
[55]
Kaser, M.; Deakin, J.B.; Michael, A.; Zapata, C.; Bansal, R.; Ryan, D.; Cormack, F.; Rowe, J.B.; Sahakian, B.J. Modafinil improves episodic memory and working memory cognition in patients with remitted depression: A double-blind, randomized, placebo-controlled study. Biol. Psychiatry Cogn. Neurosci. Neuroimaging, 2017, 2(2), 115-122.
[http://dx.doi.org/10.1016/j.bpsc.2016.11.009] [PMID: 28299368]
[56]
Turner, D. A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev. Neurother., 2006, 6(4), 455-468.
[http://dx.doi.org/10.1586/14737175.6.4.455] [PMID: 16623645]
[57]
Coogan, A.N.; Schenk, M.; Palm, D.; Uzoni, A.; Grube, J.; Tsang, A.H.; Kolbe, I.; McGowan, N.M.; Wandschneider, R.; Colla, M.; Oster, H.; Thome, J.; Faltraco, F. Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms. Neuropsychopharmacology, 2019, 44(7), 1198-1206.
[http://dx.doi.org/10.1038/s41386-019-0327-6] [PMID: 30758328]
[58]
Czeisler, C.A.; Walsh, J.K.; Wesnes, K.A.; Roth, T.; Arora, S. Armodafinil for treatment of excessive sleepiness associated with shift work disorder: A randomized controlled study. Mayo Clin. Proc., 2009, 84(11), 958-972.
[http://dx.doi.org/10.1016/S0025-6196(11)60666-6] [PMID: 19880686]
[59]
Schwartz, J.R.L.; Khan, A.; McCall, W.V.; Weintraub, J.; Tiller, J. Tolerability and efficacy of armodafinil in naïve patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder, or narcolepsy: A 12-month, open-label, flexible-dose study with an extension period. J. Clin. Sleep Med., 2010, 6(5), 450-457.
[http://dx.doi.org/10.5664/jcsm.27934] [PMID: 20957845]
[60]
Gasior, M.; Freeman, J.; Zammit, G.; Donnelly, P.; Gao, J.; Ferreira-Cornwell, M.C.; Roth, T. Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep loss. J. Clin. Psychopharmacol., 2014, 34(6), 690-696.
[http://dx.doi.org/10.1097/JCP.0000000000000202] [PMID: 25159886]
[61]
Dinges, D.F.; Arora, S.; Darwish, M.; Niebler, G.E. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr. Med. Res. Opin., 2006, 22(1), 159-167.
[http://dx.doi.org/10.1185/030079906X80378] [PMID: 16393442]
[62]
Rosenberg, R.P.; Bogan, R.K.; Tiller, J.M.; Yang, R.; Youakim, J.M.; Earl, C.Q.; Roth, T. A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorder. Mayo Clin. Proc., 2010, 85(7), 630-638.
[http://dx.doi.org/10.4065/mcp.2009.0778] [PMID: 20530317]
[63]
Harsh, J.R.; Hayduk, R.; Rosenberg, R.; Wesnes, K.A.; Walsh, J.K.; Arora, S.; Niebler, G.E.; Roth, T. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr. Med. Res. Opin., 2006, 22(4), 761-774.
[http://dx.doi.org/10.1185/030079906X100050] [PMID: 16684437]
[64]
Roth, T.; Rippon, G.A.; Arora, S. Armodafinil improves wakefulness and long-term episodic memory in nCPAP-adherent patients with excessive sleepiness associated with obstructive sleep apnea. Sleep Breath., 2008, 12(1), 53-62.
[http://dx.doi.org/10.1007/s11325-007-0137-7] [PMID: 17874255]
[65]
Page, B.R.; Shaw, E.G.; Lu, L.; Bryant, D.; Grisell, D.; Lesser, G.J.; Monitto, D.C.; Naughton, M.J.; Rapp, S.R.; Savona, S.R.; Shah, S.; Case, D.; Chan, M.D. Phase II double-blind placebo-controlled randomized study of armodafinil for brain radiation-induced fatigue. Neuro-oncol., 2015, 17(10), 1393-1401.
[http://dx.doi.org/10.1093/neuonc/nov084] [PMID: 25972454]
[66]
Bruce, J.; Hancock, L.; Roberg, B.; Brown, A.; Henkelman, E.; Lynch, S. Impact of armodafinil on cognition in multiple sclerosis: A randomized, double-blind crossover pilot study. Cogn. Behav. Neurol., 2012, 25(3), 107-114.
[http://dx.doi.org/10.1097/WNN.0b013e31826df7fd] [PMID: 22960434]
[67]
Frye, M.A.; Ketter, T.A.; Yang, R.; Calabrese, J.R. A double-blind, placebo-controlled, multicenter trial of adjunctive armodafinil for the treatment of major depression associated with bipolar I disorder. Value Health, 2013, 16(3), A55-A56.
[http://dx.doi.org/10.1016/j.jval.2013.03.1552]
[68]
Greve, D.N.; Duntley, S.P.; Larson-Prior, L.; Krystal, A.D.; Diaz, M.T.; Drummond, S.P.A.; Thein, S.G.; Kushida, C.A.; Yang, R.; Thomas, R.J. Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: A multicenter fMRI study. J. Clin. Sleep Med., 2014, 10(2), 143-153.
[http://dx.doi.org/10.5664/jcsm.3440] [PMID: 24532997]
[69]
Repantis, D.; Bovy, L.; Ohla, K.; Kühn, S.; Dresler, M. Cognitive enhancement effects of stimulants: A randomized controlled trial testing methylphenidate, modafinil, and caffeine. Psychopharmacology, 2021, 238(2), 441-451.
[http://dx.doi.org/10.1007/s00213-020-05691-w] [PMID: 33201262]
[70]
Kis, B.; Lücke, C.; van Elst, L.T.; Müller, H.H.O.; Philipsen, A.; Abdel-Hamid, M.; Heßmann, P.; Graf, E.; Berger, M.; Matthies, S.; Borel, P.; Sobanski, E.; Alm, B.; Rösler, M.; Retz, W.; Jacob, C.; Colla, M.; Huss, M.; Jans, T. Safety profile of methylphenidate under long-term treatment in adult ADHD patients - results of the COMPAS study. Pharmacopsychiatry, 2020, 53(6), 263-271.
[http://dx.doi.org/10.1055/a-1207-9851] [PMID: 33017854]
[71]
Weisler, R.; Young, J.; Mattingly, G.; Gao, J.; Squires, L.; Adler, L. Long-term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. CNS Spectr., 2009, 14(10), 573-586.
[http://dx.doi.org/10.1017/S1092852900024056] [PMID: 20095369]
[72]
Findling, R.L.; Cutler, A.J.; Saylor, K.; Gasior, M.; Hamdani, M.; Ferreira-Cornwell, M.C.; Childress, A.C. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol., 2013, 23(1), 11-21.
[http://dx.doi.org/10.1089/cap.2011.0088] [PMID: 23410138]
[73]
Bobo, W.V.; Woodward, N.D.; Sim, M.Y.; Jayathilake, K.; Meltzer, H.Y. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: A randomized, double-blind, placebo-controlled trial. Schizophr. Res., 2011, 130(1-3), 106-113.
[http://dx.doi.org/10.1016/j.schres.2011.05.015] [PMID: 21641776]
[74]
Lapid, M.I.; Kuntz, K.M.; Mason, S.S.; Aakre, J.A.; Lundt, E.S.; Kremers, W.; Allen, L.A.; Drubach, D.A.; Boeve, B.F. Efficacy, safety, and tolerability of armodafinil therapy for hypersomnia associated with dementia with lewy bodies: A pilot study. Dement. Geriatr. Cogn. Disord., 2017, 43(5-6), 269-280.
[http://dx.doi.org/10.1159/000471507] [PMID: 28448998]
[75]
Menn, S.J.; Yang, R.; Lankford, A. Armodafinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: A 12-week, randomized, double-blind study followed by a 12-month open-label extension. J. Clin. Sleep Med., 2014, 10(11), 1181-1191.
[http://dx.doi.org/10.5664/jcsm.4196] [PMID: 25325609]
[76]
Kuan, Y-C.; Wu, D.; Huang, K-W.; Chi, N-F.; Hu, C-J.; Chung, C-C.; Tam, K-W.; Huang, Y-H. Effects of modafinil and armodafinil in patients with obstructive sleep apnea: A meta-analysis of randomized controlled trials. Clin. Ther., 2016, 38(4), 874-888.
[http://dx.doi.org/10.1016/j.clinthera.2016.02.004] [PMID: 26923035]
[77]
Wisor, J.; Dement, W.; Aimone, L.; Williams, M.; Bozyczkocoyne, D. Armodafinil, the R-enantiomer of modafinil: Wake-promoting effects and pharmacokinetic profile in the rat. Pharmacol. Biochem. Behav., 2006, 85(3), 492-499.
[http://dx.doi.org/10.1016/j.pbb.2006.09.018] [PMID: 17134745]
[78]
Kreutzmann, J.C.; Havekes, R.; Abel, T.; Meerlo, P. Sleep deprivation and hippocampal vulnerability: Changes in neuronal plasticity, neurogenesis and cognitive function. Neuroscience, 2015, 309, 173-190.
[http://dx.doi.org/10.1016/j.neuroscience.2015.04.053] [PMID: 25937398]
[79]
Zhu, S.; Zhang, S.; Pang, L.; Ou, G.; Zhu, L.; Ma, J.; Li, R.; Liu, Y.; Wang, L.; Wang, L.; Du, L.; Jin, Y. Effects of armodafinil nanocrystal nasal hydrogel on recovery of cognitive function in sleep-deprived rats. Int. J. Pharm., 2021, 597, 120343.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120343] [PMID: 33545288]
[80]
Fiocchi, E.M.; Lin, Y.G.; Aimone, L.; Gruner, J.A.; Flood, D.G. Armodafinil promotes wakefulness and activates Fos in rat brain. Pharmacol. Biochem. Behav., 2009, 92(3), 549-557.
[http://dx.doi.org/10.1016/j.pbb.2009.02.006] [PMID: 19249327]
[81]
Lu, J.; Greco, M.A.; Shiromani, P.; Saper, C.B. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J. Neurosci., 2000, 20(10), 3830-3842.
[http://dx.doi.org/10.1523/JNEUROSCI.20-10-03830.2000] [PMID: 10804223]
[82]
Fuller, P.; Vetrivelan, R.; Saper, C. Armodafinil-induced wakefulness in animals with ventrolateral preoptic lesions. Nat. Sci. Sleep, 2014, 6, 57-63.
[http://dx.doi.org/10.2147/NSS.S53132] [PMID: 24833927]
[83]
Concetta Scuto, M.; Mancuso, C.; Tomasello, B.; Laura, O.M.; Cavallaro, A.; Frasca, F.; Maiolino, L.; Trovato, S.A.; Calabrese, E.J.; Calabrese, V. Curcumin, hormesis and the nervous system. Nutrients, 2019, 11(10), 2417.
[http://dx.doi.org/10.3390/nu11102417] [PMID: 31658697]
[84]
Calabrese, V.; Cornelius, C.; Dinkova-Kostova, A.T.; Calabrese, E.J.; Mattson, M.P. Cellular stress responses, the hormesis paradigm, and vitagenes: Novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid. Redox Signal., 2010, 13(11), 1763-1811.
[http://dx.doi.org/10.1089/ars.2009.3074]
[85]
Calabrese, V.; Giordano, J.; Signorile, A.; Laura Ontario, M.; Castorina, S.; De Pasquale, C.; Eckert, G.; Calabrese, E.J. Major pathogenic mechanisms in vascular dementia: Roles of cellular stress response and hormesis in neuroprotection. J. Neurosci. Res., 2016, 94(12), 1588-1603.
[http://dx.doi.org/10.1002/jnr.23925] [PMID: 27662637]
[86]
Sai, K.S.; Akkiraju, S.; Chinni, S.; Kanala, S.R. Evaluation of armodafinil’s anti-amnestic activity in scopolamine-induced amnesia in wistar rats. J. Young Pharm., 2023, 15(1), 83-91.
[http://dx.doi.org/10.5530/097515050389]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy